1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. News
  7. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy

01/11/2022 | 12:57am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALLOGENE THERAPEUTICS, INC. -1.61% 7.34 Delayed Quote.-50.00%
CELLECTIS S.A. -6.03% 3.27 Real-time Quote.-53.23%
ON SEMICONDUCTOR CORPORATION -2.49% 54.5 Delayed Quote.-17.71%
All news about CELLECTIS S.A.
11:30aGoldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating
MT
04:44aCellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022
AQ
05/23CELLECTIS S A : ' Annual Shareholders' General Meeting to be Held on June 28, 2022 - Form ..
PU
05/23Cellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022
GL
05/23Cellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022
AQ
05/23CELLECTIS S A : Consolidated Financial Statements - Form 6-K
PU
05/20CALYXT, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand..
AQ
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/19European ADRs Move Higher in Thursday Trading
MT
05/18Baird Upgrades Cellectis to Outperform From Neutral
MT
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Financials
Sales 2022 66,3 M 71,2 M 71,2 M
Net income 2022 -83,2 M -89,3 M -89,3 M
Net cash 2022 41,5 M 44,5 M 44,5 M
P/E ratio 2022 -1,48x
Yield 2022 -
Capitalization 149 M 160 M 160 M
EV / Sales 2022 1,62x
EV / Sales 2023 -1,37x
Nbr of Employees 297
Free-Float 84,3%
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,27 €
Average target price 16,00 €
Spread / Average Target 389%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Bing C. Wang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Carrie Brownstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-53.23%169
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688